论文部分内容阅读
莫西沙星(moxifloxacin)作为第四代喹诺酮类超广谱抗菌药,其最低抑菌浓度低、抗耐药特性较强,在抗结核药物中具优势和潜力。耐药结核菌群不断出现、一线药物临床疗效下降、患者顺应性差等使结核病临床治愈率低。为此,开发适合肺部介入给药的莫西沙星缓释制剂,以减少给药次数、增加患者顺应性,具有理论意义与临床价值。综述近年来出现的脂质体、微球、纳米粒子等莫西沙星缓控释制剂的国内外研究进展,为新药研发提供依据。
Moxifloxacin is the fourth generation quinolone broadspectrum antibacterial agent with low minimum inhibitory concentration (MIC) and strong anti-drug resistance. It has advantages and potential in antituberculosis drugs. Drug-resistant TB flora continues to emerge, clinical efficacy of first-line drugs, patients with poor compliance so that the clinical cure rate of tuberculosis is low. Therefore, to develop a sustained-release preparation of moxifloxacin suitable for pulmonary intervention to reduce the frequency of administration and increase patient compliance has theoretical significance and clinical value. The research progress of moxifloxacin controlled release formulations such as liposomes, microspheres and nanoparticles appeared in recent years are summarized, which provide the basis for the research and development of new drugs.